Core Viewpoint - The article highlights the breakthrough clinical data of CG-0416, a novel oral weight loss drug developed by Kejun Pharmaceutical, which targets liver metabolism and offers a new option for obesity treatment globally [5][6]. Group 1: Drug Mechanism and Advantages - CG-0416 is developed based on the thyroid hormone receptor beta (THR-β) target, demonstrating high liver targeting and promoting fat burning and energy expenditure, leading to effective reduction of liver fat accumulation [6][8]. - The drug achieves weight loss without appetite suppression, resulting in a high-quality weight loss effect characterized as "fat loss without muscle loss" [6][8]. - Clinical data shows that approximately 95% of weight loss from CG-0416 comes from fat reduction, contrasting with GLP-1 drugs where about one-third of weight loss is from muscle loss [8]. Group 2: Safety and Side Effects - CG-0416 is expected to significantly reduce gastrointestinal side effects such as nausea and vomiting, thereby improving patient compliance [8]. - The drug also lowers lipid levels in blood and liver, improving triglyceride and blood sugar tolerance, contributing to overall metabolic health benefits [8]. Group 3: Combination Therapy - Research indicates that combining CG-0416 with various GLP-1 receptor agonists, such as semaglutide, shows a strong synergistic effect, enhancing weight loss from 24% to 40% in certain models [9]. - The combination therapy alleviates muscle loss associated with standalone GLP-1 drug use, increasing the proportion of muscle post-weight loss [9]. - This dual pathway approach of central appetite regulation (GLP-1) and peripheral liver metabolism activation (CG-0416) offers a new solution for severely obese patients needing significant weight loss and metabolic remodeling [9].

9月25日，据美国临床试验登记库显示，礼来撤回了ActRIIA/B单抗bimagrumab与司美格鲁肽核心成分tirzepatide联用治疗2型糖尿病患者的IIb期 临床试验，理由是"战略业务原因"。 这项试验原计划为180名既往超重或肥胖并伴有糖尿病的受试者随机给予bimagrumab、tirzepatide或二者联用，监测70周的体重下降及脂肪/肌肉分 布，试验时间自2024年10月21日起、预计2027年1月结束。礼来强调，对所有项目进行例行评估以优化资源，并未透露试验终止的具体原因，外界 普遍解读为公司需要集中资源推进更具前景的肥胖适应症研究。 这一决定并不意味着礼来放弃bimagrumab赛道。公司仍在开展一项针对非糖尿病肥胖成人的II期试验，该试验同样评估bimagrumab与tirzepatide的 联合效果，公司发言人称结果将于2026年读出。 从时间上看，与原计划2027年结束的糖尿病试验相比，肥胖适应症读数提前一年，礼来把精力投向更有望率先获批的肥胖领域。 "高质量减重"依旧重要 bimagrumab由VersanisBio开发，可阻断ActivinⅡ型受体（ActRII），从而抑制肌肉降 ...